These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 17255829

  • 1. Natalizumab therapy for moderate to severe Crohn disease in adolescents.
    Hyams JS, Wilson DC, Thomas A, Heuschkel R, Mitton S, Mitchell B, Daniels R, Libonati MA, Zanker S, Kugathasan S, International Natalizumab CD305 Trial Group.
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):185-91. PubMed ID: 17255829
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab for active Crohn's disease.
    Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S, Natalizumab Pan-European Study Group.
    N Engl J Med; 2003 Jan 02; 348(1):24-32. PubMed ID: 12510039
    [Abstract] [Full Text] [Related]

  • 3. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.
    Gastroenterology; 2007 May 02; 132(5):1672-83. PubMed ID: 17484865
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH, Bressler B.
    Expert Rev Gastroenterol Hepatol; 2007 Oct 02; 1(1):29-39. PubMed ID: 19072431
    [Abstract] [Full Text] [Related]

  • 5. Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy.
    Dudley-Brown S, Nag A, Cullinan C, Ayers M, Hass S, Panjabi S.
    Gastroenterol Nurs; 2009 Oct 02; 32(5):327-39. PubMed ID: 19820441
    [Abstract] [Full Text] [Related]

  • 6. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar 02; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 7. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.
    Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS.
    Am J Gastroenterol; 2003 Apr 02; 98(4):833-8. PubMed ID: 12738464
    [Abstract] [Full Text] [Related]

  • 8. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
    Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zákuciová M, D'Haens G, Van Assche G, Ba S, Lee S, Pearce T.
    Gut; 2006 Aug 02; 55(8):1131-7. PubMed ID: 16507585
    [Abstract] [Full Text] [Related]

  • 9. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
    Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T.
    Gut; 2006 Aug 02; 55(8):1138-44. PubMed ID: 16492717
    [Abstract] [Full Text] [Related]

  • 10. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
    Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R, Hilton D, Hanauer SB.
    Inflamm Bowel Dis; 2007 Jan 02; 13(1):2-11. PubMed ID: 17206633
    [Abstract] [Full Text] [Related]

  • 11. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study.
    Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, Olson A, Johanns J, Marano CW, Heuschkel RB, Veereman-Wauters G, Griffiths AM, Baldassano RN, Reach Study Group.
    Clin Gastroenterol Hepatol; 2008 Dec 02; 6(12):1378-84. PubMed ID: 19081527
    [Abstract] [Full Text] [Related]

  • 12. Natalizumab induction and maintenance therapy for Crohn's disease.
    Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P, International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group, Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group.
    N Engl J Med; 2005 Nov 03; 353(18):1912-25. PubMed ID: 16267322
    [Abstract] [Full Text] [Related]

  • 13. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA, Sandrock A.
    Expert Rev Neurother; 2004 Jul 03; 4(4):571-80. PubMed ID: 15853576
    [Abstract] [Full Text] [Related]

  • 14. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease.
    Feagan BG, Sandborn WJ, Hass S, Niecko T, White J.
    Am J Gastroenterol; 2007 Dec 03; 102(12):2737-46. PubMed ID: 18042106
    [Abstract] [Full Text] [Related]

  • 15. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH.
    Crandall W, Hyams J, Kugathasan S, Griffiths A, Zrubek J, Olson A, Liu G, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano RN.
    J Pediatr Gastroenterol Nutr; 2009 Aug 03; 49(2):183-90. PubMed ID: 19561542
    [Abstract] [Full Text] [Related]

  • 16. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
    Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators.
    Neurology; 2007 Oct 02; 69(14):1391-403. PubMed ID: 17761550
    [Abstract] [Full Text] [Related]

  • 17. Natalizumab use in pediatric multiple sclerosis.
    Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J.
    Arch Neurol; 2008 Dec 02; 65(12):1655-8. PubMed ID: 19064754
    [Abstract] [Full Text] [Related]

  • 18. Effects of natalizumab, an alpha4 integrin inhibitor, on fertility in male and female guinea pigs.
    Wehner NG, Skov M, Shopp G, Rocca MS, Clarke J.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Apr 02; 86(2):108-16. PubMed ID: 19283862
    [Abstract] [Full Text] [Related]

  • 19. Immunotoxicity profile of natalizumab.
    Wehner NG, Gasper C, Shopp G, Nelson J, Draper K, Parker S, Clarke J.
    J Immunotoxicol; 2009 Jun 02; 6(2):115-29. PubMed ID: 19589098
    [Abstract] [Full Text] [Related]

  • 20. Clinical evaluation of natalizumab for formulary consideration.
    Bivins A, Hou K, Ayesu N, Ellsworth B, Montenegro S, Tu X, Boyle C, Dowling T, Shaya FT.
    Expert Opin Biol Ther; 2010 Aug 02; 10(8):1279-87. PubMed ID: 20626228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.